Stanley-Laman Group’s AIM ImmunoTech AIM Stock Holding History

Stanley-Laman Group’s Portfolio AIM Stock Details AIM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-130	Closed	-$32K	–	263
2020 Q2	$32K	Buy	+130	New	+$31.6K	0.01%	233

Other funds holding AIM

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

GCP

GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return

HighTower Advisors Chicago, Illinois $94.2B AUM 21.24% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

SWM

SeaCrest Wealth Management Purchase, New York $903M AUM 47.26% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Stanley-Laman Group's AIM Position: Q3 2020 in Review

Stanley-Laman Group sold out of AIM ImmunoTech (AIM) in Q3 2020, closing a stake of 130 shares — an estimated $32K sold.

Stanley-Laman Group first reported a position in AIM in Q2 2020 and held it in 1 quarter. The position peaked at $32K in Q2 2020. 32 funds tracked by Wall St. Rank hold AIM as of Q3 2020.

Stanley-Laman Group reported no remaining AIM ImmunoTech position as of Q3 2020 after selling out during the quarter.
Stanley-Laman Group sold 130 AIM ImmunoTech shares in Q3 2020, an estimated $32K.
Stanley-Laman Group first reported a position in AIM ImmunoTech in Q2 2020 and held it in 1 quarter.
Stanley-Laman Group's AIM ImmunoTech position peaked at $32K in Q2 2020.
32 funds tracked by Wall St. Rank held AIM ImmunoTech as of Q3 2020.

Based on Stanley-Laman Group's 13F filing for Q3 2020, filed 20 Oct 2020.